The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ratio ...

NICE has recommended rucaparib as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

The median progression-free survival was 15.0 months in patients who received nivolumab plus rucaparib and 20.2 months in patients who received rucaparib alone. Adding nivolumab to rucaparib ...

PARP inhibitors, which are now used as a first-line management in newly diagnosed individuals, include the FDA-approved olaparib, as well as rucaparib and niraparib. Ovarian cancer is the eighth ...

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change that. At ASCO, AZ ...

TIME's senior sports correspondent Sean Gregory tries his hand at several Olympic sports while learning from Olympians. Subscribe now to get unlimited access to TIME.com and more! Tidal action ...

Rayne Beau, a lost cat, managed to travel 800 miles back home after vanishing during a camping trip in Yellowstone National Park. Found exhausted in Roseville, California, he was reunited with his ...

After two days of exploding pagers and walkie-talkies, Beirut was a city on edge, with people worried there were bombs in their bags or pockets. Victims’ relatives vowed retribution. By Hwaida ...